| Literature DB >> 30127859 |
Dan Li1,2, Min Shen3, Ying Xu4, Chao Liu3, Wen Wang5, Jinyan Wu3, Xianmei Luo3, Xu Jia3, Yongxin Ma1.
Abstract
BACKGROUND: Diarrheagenic Escherichia coli (DEC) is one of the most important etiological agents of diarrheal diseases. In this study we investigated the prevalence, virulence gene profiles, antimicrobial resistance, and molecular genetic characteristics of DEC at a hospital in western China.Entities:
Keywords: Antimicrobial resistance; Diarrhea; Escherichia coli; Molecular genetics; Virulence genes
Year: 2018 PMID: 30127859 PMCID: PMC6097206 DOI: 10.1186/s13099-018-0262-9
Source DB: PubMed Journal: Gut Pathog ISSN: 1757-4749 Impact factor: 4.181
Distribution of virulence gene incidence among DEC
| DEC group | Virulence genes, | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| DAEC | 100 (9) | 100 (9) | 100 (9) | 100 (9) | 44.44 (4) | 44.44 (4) | 0 (0) |
| EAEC | 100 (4) | 100 (4) | 100 (4) | 100 (4) | 50 (2) | 50 (2) | 75 (3) |
Fig. 1Frequency of virulence genes among DEC isolates
Antimicrobial resistance among DEC
| Antibiotic | DAEC | EAEC | ||
|---|---|---|---|---|
|
|
|
|
| |
| SSS | 100 | 9 | 100 | 4 |
| DOX | 100 | 9 | 75 | 3 |
| TET | 100 | 9 | 75 | 3 |
| CTX | 88.89 | 8 | 25 | 1 |
| AMP | 88.89 | 8 | 75 | 3 |
| TIC | 88.89 | 8 | 75 | 3 |
| NA | 77.78 | 7 | 100 | 4 |
| CFP | 66.67 | 6 | 25 | 1 |
| PIP | 66.67 | 6 | 50 | 2 |
| GEN | 55.56 | 5 | 50 | 2 |
| CIP | 55.56 | 5 | 0 | 0 |
| LEV | 44.44 | 4 | 0 | 0 |
| OFX | 44.44 | 4 | 0 | 0 |
| TOB | 33.33 | 3 | 25 | 1 |
| FOX | 22.22 | 2 | 0 | 0 |
| CAZ | 22.22 | 2 | 0 | 0 |
| MIN | 22.22 | 2 | 50 | 2 |
| ATM | 22.22 | 2 | 0 | 0 |
| KAN | 11.11 | 1 | 25 | 1 |
| AMK | 0 | 0 | 0 | 0 |
| MERO | 0 | 0 | 0 | 0 |
| IMP | 0 | 0 | 0 | 0 |
| ETP | 0 | 0 | 0 | 0 |
SSS sulfonamide, DOX doxycycline, TET tetracycline, CTX cefotaxime, AMP ampicillin, TIC ticarcillin, NA nalidixic acid, CFP cefoperazone, PIP piperacillin, GEN gentamicin, CIP ciprofloxacin, LEV levofloxacin, OFX ofloxacin, TOB tobramycin, FOX cefoxitin, CAZ ceftazidime, MIN minocycline, ATM aztreonam, KAN kanamycin, AMK amikacin, MERO meropenem, IMP imipenem, ETP ertapenem
Frequency of virulence genes among antimicrobial resistant DAEC isolates
| Antibiotic (n) | Virulence genes, | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| SSS (9) | 100 (9) | 100 (9) | 100 (9) | 100 (9) | 44.44 (4) | 44.44 (4) |
| DOX (9) | 100 (9) | 100 (9) | 100 (9) | 100 (9) | 44.44 (4) | 44.44 (4) |
| TET (9) | 100 (9) | 100 (9) | 100 (9) | 100 (9) | 44.44 (4) | 44.44 (4) |
| CTX (8) | 100 (8) | 100 (8) | 100 (8) | 100 (8) | 50 (4) | 37.5 (3) |
| AMP (8) | 100 (8) | 100 (8) | 100 (8) | 100 (8) | 50 (4) | 37.5 (3) |
| TIC (8) | 100 (8) | 100 (8) | 100 (8) | 100 (8) | 50 (4) | 37.5 (3) |
| NA (7) | 100 (7) | 100 (7) | 100 (7) | 100 (7) | 42.86 (3) | 57.14 (4) |
| CFP (6) | 100 (6) | 100 (6) | 100 (6) | 100 (6) | 33.33 (2) | 50 (3) |
| PIP (6) | 100 (6) | 100 (6) | 100 (6) | 100 (6) | 33.33 (2) | 50 (3) |
| GEN (5) | 100 (5) | 100 (5) | 100 (5) | 100 (5) | 40 (2) | 40 (2) |
| CIP (5) | 100 (5) | 100 (5) | 100 (5) | 100 (5) | 40 (2) | 40 (2) |
| LEV (4) | 100 (4) | 100 (4) | 100 (4) | 100 (4) | 25 (1) | 50 (2) |
| OFX (4) | 100 (4) | 100 (4) | 100 (4) | 100 (4) | 25 (1) | 50 (2) |
| TOB (3) | 100 (3) | 100 (3) | 100 (3) | 100 (3) | 0 (0) | 66.67 (2) |
| FOX (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 50 (1) | 0 (0) |
| CAZ (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 0 (0) | 50 (1) |
| MIN (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 50 (1) | 50 (1) |
| ATM (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 0 (0) | 50 (1) |
| KAN (1) | 100 (1) | 100 (1) | 100 (1) | 100 (1) | 0 (0) | 100 (1) |
SSS sulfonamide, DOX doxycycline, TET tetracycline, CTX cefotaxime, AMP ampicillin, TIC ticarcillin, NA nalidixic acid, CFP cefoperazone, PIP piperacillin, GEN gentamicin, CIP ciprofloxacin, LEV levofloxacin, OFX ofloxacin, TOB tobramycin, FOX cefoxitin, CAZ ceftazidime, MIN minocycline, ATM aztreonam, KAN kanamycin
Frequency of virulence genes among antimicrobial resistant EAEC isolates
| Antibiotic (n) | Virulence genes, | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| SSS (4) | 100 (4) | 100 (4) | 100 (4) | 100 (4) | 75 (3) | 50 (2) | 50 (2) |
| NA (4) | 100 (4) | 100 (4) | 100 (4) | 100 (4) | 75 (3) | 50 (2) | 50 (2) |
| DOX (3) | 100 (3) | 100 (3) | 100 (3) | 100 (3) | 50 (2) | 25 (1) | 25 (1) |
| TET (3) | 100 (3) | 100 (3) | 100 (3) | 100 (9) | 50 (2) | 25 (1) | 25 (1) |
| AMP (3) | 100 (3) | 100 (3) | 100 (3) | 100 (3) | 50 (2) | 25 (1) | 25 (1) |
| TIC (3) | 100 (3) | 100 (3) | 100 (3) | 100 (3) | 50 (2) | 25 (1) | 25 (1) |
| GEN (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 25 (1) | 0 (0) | 0 (0) |
| MIN (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 25 (1) | 25 (1) | 25 (1) |
| PIP (2) | 100 (2) | 100 (2) | 100 (2) | 100 (2) | 25 (1) | 25 (1) | 25 (1) |
| TOB (1) | 100 (1) | 100 (1) | 100 (1) | 100 (1) | 0 (0) | 0 (0) | 0 (0) |
| KAN (1) | 100 (1) | 100 (1) | 100 (1) | 100 (1) | 0 (0) | 0 (0) | 0 (0) |
| CFP (1) | 100 (1) | 100 (1) | 100 (1) | 100 (1) | 0 (0) | 0 (0) | 0 (0) |
| CTX (1) | 100 (1) | 100 (1) | 100 (1) | 100 (1) | 0 (0) | 0 (0) | 0 (0) |
SSS sulfonamide, NA nalidixic acid, DOX doxycycline, TET tetracycline, AMP ampicillin, TIC ticarcillin, GEN gentamicin, MIN minocycline, PIP piperacillin, TOB tobramycin, KAN kanamycin, CFP cefoperazone, CTX cefotaxime
Fig. 2PFGE profiles of 13 DEC. The isolate number, DEC pathotype, PFGE pattern, sequence type (ST), virulence genes (fimC, fimH, fyuA, irp2, hlyA, sat, and cnf1) and multidrug resistance (MDR) are listed on the right. “+” indicates gene positive or MDR; “−” indicates gene negative or not MDR
Gene primers used in this study
| Gene | Primer sequence (5′-3′) | PCR product (bp) | References |
|---|---|---|---|
|
| F: CTGGAAGAGGCTAGCCTGGACGAG | 369 | [ |
|
| F: GGGTATTGTCCGTTCCGAT | 1176 | [ |
|
| F: CCATCAACACAGTATATCCGA | 111 | [ |
|
| F: ACGCAGAGTTGCCTGATAAAG | 400 | [ |
|
| F: CGATGTTACGGTTTGTTACTGTGACAGC | 244 | [ |
|
| F: GTTTTGACCATCTTCGTCTGATTATTGAG | 324 | [ |
|
| F: TGAGCGGCTGGCATGAGTCATAC | 241 | [ |
|
| F: GACACCTCATTGCTGAAGTCG | 324 | [ |
|
| F: GTTCCTTGACCGCCTTTCCGATACCGTC | 619 | [ |
|
| F: ATTTTTCTTTCTGTATTGTCTT | 190 | [ |
|
| F: GGCGACAGATTATACCGTGC | 450 | [ |
|
| F: TGAACGGGAGTATAAGGAAGATG | 444 | [ |
|
| F: GAACGTTGGTTAATGTGGGGTAA | 542 | [ |
|
| F: GGGTAGAAAATGCCGATGGTG | 477 | [ |
|
| F: CGAGTTATTACCCTGTTTGCTG | 878 | [ |
|
| F: GCTAACGCTGCGTTAGAAAGACC | 421 | [ |
|
| F: ATGTATTTTTAGAGGTTGAC | 518 | [ |
|
| F: GTATCATTGCGAGTCTGGTATTCAG | 462 | [ |
|
| F: TGAGTTGTGGGGCTAYCTGGACACC | 169 | [ |
|
| F: AGGCGGTGCATTCACTCTGGCATCT | 446 | [ |
|
| F: CTCCGGAGAACTGGGTGCATCTTAC | 408 | [ |
|
| F: GACGGCTGTACTGCAGGGTGTGGCG | 328 | [ |
|
| F: AAGGATTCGCTGTTACCGGAC | 264 | [ |
|
| F: TGATTAACCCCGCGACGGGAA | 785 | [ |
|
| F: CACTAAGCTCGATATATAGAACCC | 824 | [ |
|
| F: CGCCTTTTACAAGATAGAAC | 854 | [ |
|
| F: GATGACATCATGAATAAACTC | 2128 | [ |
|
| F: AAACAGCAGGCACTTGAACG | 1830 | [ |
|
| F: GGAAGTTTGTTTACAGAGACG | 297 | [ |
|
| F: GTATAACCAGAGGAGTAGC | 260 | [ |
|
| F: GAATAACAATCACTCCTCACC | 233 | [ |
|
| F: GGCGACAAATGCAGTATTGCTTGG | 552 | [ |
|
| F: GTGAGGCTCAACGAGATTATGCACTG | 839 | [ |
| F: CAATAGTCGCCCACAGGA | 412 | [ | |
| F: GAAAGTAAATGGAATATAAATGTCCG | 556 | [ | |
|
| F:CGATCAAGAATCCCTAACAGAAGAATCAC | 766 | [ |
|
| F: GCATCATCAAGCGTACGTTCC | 533 | [ |
|
| F: TTTCCAGCACTTCCTGTTCC | 297 | [ |
|
| F: GCAGCAAATATTGATATATCA | 2913 | [ |
|
| F: TATGGCTTCCCTCATTGCC | 556 | [ |